Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (279)	9/25/2000 11:30:23 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

thanks for posting this..... >> Previously, scientists were limited to studying protein-protein interactions in model systems of lower organisms, such as yeast. << Yeah, they were forced to use those convenient, fast model systems. >> "...... serves as an important addition to research conducted in yeast and other model systems, which alone do not always translate well into human biology" << Hmmmmm..... you engineer a cell and see protein-protein interaction of interest. Seems to me that, if you've got an antagonist, you've got a hit. The Cadus system is proven to work. Seems to me that, if you have a hit in yeast, your odds are good that it's a hit. I can see situations where endogenous components might prevent one from seeing the relevant protein-protein interaction in the first place..... I doubt that yeast folks ever claimed that it would always work. Glass..... could you issue a letter to shareholders, letting us know what in heck is going on? Is there any attempt to cross-license with Cyanamide? Is that a silly question, or is it relevant? You've lost contact with your shareholders to an extreme. We have no concept of what you are doing, or if you are doing anything.